RotaTeq® and Meningococcus C Vaccine in Healthy Infants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00443846
Recruitment Status : Completed
First Posted : March 6, 2007
Last Update Posted : March 16, 2017
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

March 5, 2007
March 6, 2007
March 16, 2017
February 2007
April 2008   (Final data collection date for primary outcome measure)
Seroprotection response for the meningococcal Group C serotype [ Time Frame: 28 to 42 days post vaccination ]
Seroprotection response for the meningococcal Group C serotype
Complete list of historical versions of study NCT00443846 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
RotaTeq® and Meningococcus C Vaccine in Healthy Infants
An Open-label, Randomised, Comparative, Multi-centre Study of the Immunogenicity and Safety of the Concomitant Use of a Live Pentavalent Rotavirus Vaccine (RotaTeq®) and a Meningococcal Group C Conjugate (MCC) Vaccine in Healthy Infants

Primary objective:

To check if RotaTeq® can be administered concomitantly with meningococcal Group C vaccine without impairing the efficacy of MCC vaccine.

Secondary objectives:

  • Efficacy: Additional immunogenicity assessments.
  • Safety: To describe the safety profile of RotaTeq® and of the MCC vaccine when administered concomitantly with RotaTeq®.
Not Provided
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
  • Meningitis, Meningococcal
  • Rotavirus Infections
  • Biological: RotaTeq®
  • Biological: NeisVac-C®
  • Experimental: Group 1
    Concomitant administration
    • Biological: RotaTeq®
    • Biological: NeisVac-C®
  • Active Comparator: Group 2
    Staggered administration
    • Biological: RotaTeq®
    • Biological: NeisVac-C®
Vesikari T, Karvonen A, Borrow R, Kitchin N, Baudin M, Thomas S, Fiquet A. Results from a randomized clinical trial of coadministration of RotaTeq, a pentavalent rotavirus vaccine, and NeisVac-C, a meningococcal serogroup C conjugate vaccine. Clin Vaccine Immunol. 2011 May;18(5):878-84. doi: 10.1128/CVI.00437-10. Epub 2011 Mar 9.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
April 2008
April 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy infants, aged from 6 weeks through full 7 weeks,
  • Consent form signed by at least one parent or by the legal representative properly informed about the study,
  • Parent(s) / legal representative able to understand the protocol requirements and to fill in the Diary Card.

Exclusion Criteria:

  • History of congenital abdominal disorders, congenital malformation of the gastrointestinal tract that could predispose to intussusception, or abdominal surgery,
  • Congenital fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency,
  • Known or suspected impairment of immunological function,
  • Known hypersensitivity to any component of RotaTeq® (e.g. sucrose) or of NeisVac-C® (including tetanus toxoid),
  • Prior administration of any rotavirus vaccine,
  • Prior administration of any vaccine within the 28 days prior to randomisation,
  • Fever (rectal temperature ≥38.1°C) and/or acute diarrhoea and/or vomiting at randomisation,
  • History of known prior rotavirus gastroenteritis, chronic diarrhoea, or failure to thrive,
  • Any severe thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injection,
  • Clinical evidence of active gastrointestinal illness,
  • Receipt of intramuscular, oral, or intravenous corticosteroid treatment within the 14 days prior to randomisation. Note: Infants on inhaled and/or topical steroids may participate in the study,
  • Infants residing in a household with an immunocompromised person,
  • Prior receipt of a blood transfusion or blood products, including immunoglobulins.
Sexes Eligible for Study: All
42 Days to 56 Days   (Child)
Contact information is only displayed when the study is recruiting subjects
S06-ROT-304 ( Other Identifier: MCMVaccBV (SPMSD) Protocol Number )
Not Provided
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Study Director: Anne FIQUET, MD SPMSD
Merck Sharp & Dohme Corp.
March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP